OncoMatch/Clinical Trials/NCT06572813
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Is NCT06572813 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Bortezomib and Sintilimab for pancreas cancer.
Treatment: Bortezomib · Sintilimab · mFOLFIRINOX — This is an single-center, prospective, open-label clinical trial, to explore the safty and efficacy of combination of Bortezomib, Sindilizumab, and mFOLFIRINOX Chemotherapy (oxaliplatin, fluorouracil, irinotecan, leucovorin) in metastatic pancreatic cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: Gemcitabine-based chemotherapy as first line allowed if progressed
Never receive any systematic treatment or Progression after fisrt line Gemcitabine base chemotherapy
Cannot have received: chemotherapy
History of receiving chemotherapy within 2 weeks
Cannot have received: radiation therapy
History of radiotherapy and molecular target therapy within 2 weeks
Cannot have received: targeted therapy
History of radiotherapy and molecular target therapy within 2 weeks
Lab requirements
Kidney function
Serum creatinine level is normal
Liver function
serum total bilirubin level is less than 1.5 x ULN; ALT and AST are less than 2 x ULN
Serum creatinine level is normal, and serum total bilirubin level is less than 1.5 x ULN. ALT and AST are less than 2 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify